Here are Tuesday's biggest analyst calls of the day: Nvidia, Broadcom, Tesla, Lowe's, Disney, Intel & more

Wall Street calls were broadly constructive, with multiple upgrades and initiations at Buy/Overweight across tech, healthcare, industrials, and energy names. Notable target increases included Broadcom to $500, Nvidia to $315 and $275, Intel to $100, and Lowe's upgraded to Buy ahead of earnings, while Tesla delivery checks improved to +7% y/y in April. Overall tone was positive for individual stocks, but the piece is primarily analyst commentary rather than a single market-moving catalyst.

Analysis

This read-through is less about isolated upgrades and more about a coordinated “quality growth + AI capex + defensive software + selective cyclicals” bid. The semis calls on AVGO/NVDA suggest the Street is moving past peak-concern framing and toward FY27/FY28 visibility, which matters because multiples can re-rate before earnings inflect if guidance de-risks the next two quarters. If that view holds, the second-order winner is the picks-and-shovels layer in infrastructure and networking, while the loser is anyone still anchored to a mid-cycle semis de-rating.

The software upgrades on ADSK and BSY are notable because they imply investors may be underestimating the persistence of workflow moat versus AI substitution risk. In practice, the market is likely overpaying for “AI winners” and underpricing firms whose data gravity makes them harder to automate away; that creates room for multiple expansion even without dramatic revenue acceleration. The same logic applies to DIS: the setup is not about a great consumer tape, but about whether margin structure can quietly improve enough to change the valuation regime over the next 2-3 quarters.

In healthcare, the multiple initiations across PODD/DXCM/BNTC point to a renewed willingness to pay for differentiated device and biologics platforms, but the dispersion is key: the easiest money is likely in the incumbent platform names if sentiment is improving, while smaller-cap rare disease stories remain binary and financing-sensitive. Energy and industrial cyclicals like MTDR, SR, CE, and BAK look like classic late-cycle mean reversion trades, but the real catalyst is not demand improvement—it’s supply discipline and balance-sheet repair, which can sustain margin tails longer than consensus expects. The weakest signal in the set is TSLA: better delivery checks help near-term optics, but they do not yet solve the core margin/price-compression problem, so upside is more tactical than structural.

Contrarian takeaway: the Street may be overconfident that “visibility” is enough to justify higher multiples across semis and software simultaneously. If rates stop easing or growth data wobbles, crowded quality-growth longs could de-rate together, while the cheaper cyclicals with improving fundamentals may outperform on a 3-6 month basis.

Key Decisions for Investors

• Add AVGO vs. short SMH on a 1-3 month horizon: AVGO has the clearest earnings-visibility re-rating path, while the ETF is more exposed if the market rotates out of crowded AI beta; target 8-12% relative outperformance if semi multiples hold.
• Initiate a long NVDA / long-dated put spread hedge into earnings: the setup favors upside on guide, but the tape is pricing perfection; use a 30-45 day structure to capture the event while limiting gap risk.
• Pair long ADSK or BSY vs. short a basket of unprofitable AI software names over 3-6 months: the market is starting to distinguish defensible workflow software from automation-vulnerable applications, with better asymmetry in the profitable incumbents.
• Trade MTDR and CE as tactical longs for 1-2 quarters, but size modestly: these are margin-recovery trades, not secular compounders; use stop-losses if crude/chemical spreads roll over or if broader macro weakens.
• For TSLA, prefer short-dated call spreads only into delivery catalysts rather than outright long stock: improved checks support a bounce, but the risk/reward remains capped until pricing power stabilizes.